Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | The role of elotuzumab-based combinations in multiple myeloma therapy

Michael Slade • 15 Feb 2023
Tandem Meetings 2023
Multiple Myeloma Antibodies Daratumumab Dexamethasone Elotuzumab Isatuximab Pomalidomide

Michael Slade, MD, Washington University School of Medicine, St Louis, MO, talks on the role of elotuzumab-based therapies in multiple myeloma, explaining that its place in the treatment algorithm of multiple myeloma remains unclear. Nevertheless, anecdotal evidence suggests that elotuzumab-based triplet combinations appear to be more beneficial in patients with slowly progressing disease. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Slade

2:10
Phase II study of EPd maintenance after second autologous transplant for multiple myeloma
Michael Slade • 15 Feb 2023
1:27
The use of salvage second autologous transplant in the age of novel therapies for multiple myeloma
Michael Slade • 15 Feb 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals